View ValuationEpigral 향후 성장Future 기준 점검 3/6Epigral (는) 각각 연간 16.1% 및 20.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 16.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 16.4% 로 예상됩니다.핵심 정보16.1%이익 성장률16.12%EPS 성장률Chemicals 이익 성장19.4%매출 성장률20.2%향후 자기자본이익률16.40%애널리스트 커버리지Low마지막 업데이트03 May 2026최근 향후 성장 업데이트Price Target Changed • Jan 07Price target decreased by 23% to ₹2,000Down from ₹2,600, the current price target is provided by 1 analyst. New target price is 73% above last closing price of ₹1,156. Stock is down 37% over the past year. The company posted earnings per share of ₹84.68 last year.모든 업데이트 보기Recent updatesNew Risk • May 18New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.공시 • May 14Epigral Limited, Annual General Meeting, Jun 08, 2026Epigral Limited, Annual General Meeting, Jun 08, 2026, at 11:00 Indian Standard Time.Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹76.95 (vs ₹84.68 in FY 2025)Full year 2026 results: EPS: ₹76.95 (down from ₹84.68 in FY 2025). Revenue: ₹25.4b (flat on FY 2025). Net income: ₹3.32b (down 7.2% from FY 2025). Profit margin: 13% (in line with FY 2025). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 12% per year.공시 • Apr 29Epigral Limited to Report Q4, 2026 Results on May 02, 2026Epigral Limited announced that they will report Q4, 2026 results at 9:08 AM, Indian Standard Time on May 02, 2026Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹951, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 25x in the Chemicals industry in India. Negligible returns to shareholders over past three years.Reported Earnings • Jan 31Third quarter 2026 earnings released: EPS: ₹9.07 (vs ₹24.25 in 3Q 2025)Third quarter 2026 results: EPS: ₹9.07 (down from ₹24.25 in 3Q 2025). Revenue: ₹5.97b (down 7.5% from 3Q 2025). Net income: ₹391.1m (down 62% from 3Q 2025). Profit margin: 6.5% (down from 16% in 3Q 2025). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.공시 • Jan 20Epigral Limited to Report Q3, 2026 Results on Jan 30, 2026Epigral Limited announced that they will report Q3, 2026 results on Jan 30, 2026Price Target Changed • Jan 07Price target decreased by 23% to ₹2,000Down from ₹2,600, the current price target is provided by 1 analyst. New target price is 73% above last closing price of ₹1,156. Stock is down 37% over the past year. The company posted earnings per share of ₹84.68 last year.Reported Earnings • Nov 11Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2026 results: EPS: ₹11.87 (down from ₹19.57 in 2Q 2025). Revenue: ₹5.89b (down 5.9% from 2Q 2025). Net income: ₹512.2m (down 37% from 2Q 2025). Profit margin: 8.7% (down from 13% in 2Q 2025). The decrease in margin was driven by lower revenue. Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) missed analyst estimates by 16%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 7% per year.공시 • Nov 04Epigral Limited to Report Q2, 2026 Results on Nov 10, 2025Epigral Limited announced that they will report Q2, 2026 results on Nov 10, 2025Reported Earnings • Aug 03First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2026 results: EPS: ₹37.25 (up from ₹20.67 in 1Q 2025). Revenue: ₹6.07b (down 6.9% from 1Q 2025). Net income: ₹1.61b (up 87% from 1Q 2025). Profit margin: 27% (up from 13% in 1Q 2025). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 98%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹2,085, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 43% over the past three years.공시 • Jul 28Epigral Limited to Report Q1, 2026 Results on Aug 02, 2025Epigral Limited announced that they will report Q1, 2026 results at 9:08 AM, Indian Standard Time on Aug 02, 2025공시 • Jun 30Epigral Limited Approves Final Dividend for the Financial Year Ended 31 March, 2025Epigral Limited announced that at its AGM held on June 28, 2025, approved payment of Interim Dividend of INR 2.50 (25%) per equity share of INR 10 each and to declare Final Dividend of INR 3.50 (35%) per equity share of INR 10 each fully paid-up for the Financial Year ended 31st March, 2025.Upcoming Dividend • Jun 16Upcoming dividend of ₹3.50 per shareEligible shareholders must have bought the stock before 20 June 2025. Payment date: 28 July 2025. Payout ratio is a comfortable 7.1% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).Reported Earnings • Jun 09Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: EPS: ₹84.68 (up from ₹47.14 in FY 2024). Revenue: ₹25.5b (up 32% from FY 2024). Net income: ₹3.58b (up 83% from FY 2024). Profit margin: 14% (up from 10% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) exceeded analyst estimates by 3.8%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.Declared Dividend • Jun 02Final dividend of ₹3.50 announcedShareholders will receive a dividend of ₹3.50. Ex-date: 20th June 2025 Payment date: 28th July 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (12% cash payout ratio). The dividend has increased by an average of 18% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 71% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공시 • May 30Epigral Limited, Annual General Meeting, Jun 28, 2025Epigral Limited, Annual General Meeting, Jun 28, 2025, at 10:30 Indian Standard Time.Reported Earnings • May 07Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: EPS: ₹84.68 (up from ₹47.14 in FY 2024). Revenue: ₹25.7b (up 33% from FY 2024). Net income: ₹3.58b (up 83% from FY 2024). Profit margin: 14% (up from 10% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) exceeded analyst estimates by 3.8%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.공시 • Apr 23Epigral Limited to Report Q4, 2025 Results on May 05, 2025Epigral Limited announced that they will report Q4, 2025 results on May 05, 2025New Risk • Mar 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (64% net debt to equity). Share price has been volatile over the past 3 months (8.1% average weekly change).Valuation Update With 7 Day Price Move • Mar 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹1,866, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 26x in the Chemicals industry in India. Total returns to shareholders of 112% over the past three years.공시 • Feb 28Epigral Limited Announces Cessation of Bhavin Parikh as an Independent Woman DirectorThe Board of Directors of Epigral Limited vide Circular Resolution, passed on 28th February, 2025, have inter-alia considered and approved cessation of Ms. Nirali Bhavin Parikh as an Independent Woman Director of the Company with effect from close of business hours on 28th February, 2025 pursuant to completion of her second term of five consecutive years.Upcoming Dividend • Jan 31Upcoming dividend of ₹2.50 per shareEligible shareholders must have bought the stock before 07 February 2025. Payment date: 26 February 2025. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).Reported Earnings • Jan 28Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: EPS: ₹24.25 (up from ₹11.81 in 3Q 2024). Revenue: ₹6.49b (up 38% from 3Q 2024). Net income: ₹1.04b (up 111% from 3Q 2024). Profit margin: 16% (up from 10% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) also surpassed analyst estimates by 25%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.공시 • Jan 27Epigral Limited Declares Interim Dividend for the Financial Year 2024-25Epigral Limited announced at the SBM held on January 27, 2025, the board approved declared interim dividend of INR 2.50 (25%) per Equity Share of face value of INR 10 each for the Financial Year 2024-25 and has fixed 7th February, 2025 as `Record Date' pursuant to regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for ascertaining eligibility of Members for the payment of aforesaid Interim Dividend.공시 • Jan 18Epigral Limited to Report Q3, 2025 Results on Jan 27, 2025Epigral Limited announced that they will report Q3, 2025 results on Jan 27, 2025Reported Earnings • Nov 10Second quarter 2025 earnings released: EPS: ₹19.57 (vs ₹9.14 in 2Q 2024)Second quarter 2025 results: EPS: ₹19.57 (up from ₹9.14 in 2Q 2024). Revenue: ₹6.32b (up 32% from 2Q 2024). Net income: ₹813.0m (up 114% from 2Q 2024). Profit margin: 13% (up from 7.9% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India.공시 • Oct 31Epigral Limited to Report Q2, 2025 Results on Nov 09, 2024Epigral Limited announced that they will report Q2, 2025 results at 12:08 PM, Indian Standard Time on Nov 09, 2024Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹2,296, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 197% over the past three years.New Risk • Sep 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (77% net debt to equity). Share price has been volatile over the past 3 months (8.7% average weekly change).Reported Earnings • Jul 25First quarter 2025 earnings released: EPS: ₹20.67 (vs ₹7.58 in 1Q 2024)First quarter 2025 results: EPS: ₹20.67 (up from ₹7.58 in 1Q 2024). Revenue: ₹6.51b (up 43% from 1Q 2024). Net income: ₹858.7m (up 173% from 1Q 2024). Profit margin: 13% (up from 6.9% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in India.공시 • Jul 16Epigral Limited to Report Q1, 2025 Results on Jul 24, 2024Epigral Limited announced that they will report Q1, 2025 results on Jul 24, 2024공시 • Jul 10Epigral Limited Approves Final Dividend for the Financial Year 2024Epigral Limited announced that at its Annual General Meeting held on July 9, 2024, approved final dividend of INR 5.00 (50%) per equity share of INR 10 each for the Financial Year 2023-2024.Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹1,559, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 49% over the past year.Upcoming Dividend • Jun 27Upcoming dividend of ₹5.00 per shareEligible shareholders must have bought the stock before 02 July 2024. Payment date: 08 August 2024. Payout ratio is a comfortable 11% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.7%).Reported Earnings • Jun 20Full year 2024 earnings released: EPS: ₹47.14 (vs ₹85.03 in FY 2023)Full year 2024 results: EPS: ₹47.14 (down from ₹85.03 in FY 2023). Revenue: ₹19.3b (down 12% from FY 2023). Net income: ₹1.96b (down 45% from FY 2023). Profit margin: 10% (down from 16% in FY 2023). The decrease in margin was driven by lower revenue.Declared Dividend • Jun 13Dividend of ₹5.00 announcedShareholders will receive a dividend of ₹5.00. Ex-date: 2nd July 2024 Payment date: 8th August 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (11% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 13% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공시 • Jun 13Epigral Limited, Annual General Meeting, Jul 09, 2024Epigral Limited, Annual General Meeting, Jul 09, 2024, at 10:30 Indian Standard Time.Board Change • Jun 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 6 highly experienced directors. Independent Non-Executive Director Kanubhai Patel was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 23Full year 2024 earnings released: EPS: ₹47.13 (vs ₹85.03 in FY 2023)Full year 2024 results: EPS: ₹47.13 (down from ₹85.03 in FY 2023). Revenue: ₹19.4b (down 12% from FY 2023). Net income: ₹1.96b (down 45% from FY 2023). Profit margin: 10% (down from 16% in FY 2023). The decrease in margin was driven by lower revenue.공시 • Apr 23+ 1 more updateEpigral Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024Epigral Limited Recommended final dividend of INR 5.00(50.00%) per equity share on 4,15,50,158 Equity Shares of INR 10/- each for the financial year ended 31st March, 2024, subject to approval of the Shareholders of the Company at the forthcoming Annual General Meeting. The Book Closure and Record Date for this purpose will be intimated in due course.공시 • Apr 10Epigral Limited to Report Q4, 2024 Results on Apr 22, 2024Epigral Limited announced that they will report Q4, 2024 results on Apr 22, 2024Valuation Update With 7 Day Price Move • Apr 02Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹1,323, the stock trades at a trailing P/E ratio of 28.2x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 38% over the past year.Valuation Update With 7 Day Price Move • Feb 21Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹1,219, the stock trades at a trailing P/E ratio of 26x. Average forward P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 21% over the past year.Reported Earnings • Jan 26Third quarter 2024 earnings released: EPS: ₹11.81 (vs ₹18.58 in 3Q 2023)Third quarter 2024 results: EPS: ₹11.81 (down from ₹18.58 in 3Q 2023). Revenue: ₹4.72b (down 12% from 3Q 2023). Net income: ₹490.8m (down 36% from 3Q 2023). Profit margin: 10% (down from 14% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India.Buy Or Sell Opportunity • Jan 25Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 9.0% to ₹998. The fair value is estimated to be ₹812, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last year. Earnings per share has declined by 39%.공시 • Jan 02Epigral Limited to Report Q3, 2024 Results on Jan 24, 2024Epigral Limited announced that they will report Q3, 2024 results on Jan 24, 2024New Risk • Nov 07New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 11% Last year net profit margin: 18% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks High level of debt (85% net debt to equity). Short dividend paying track record (1 year of continuous dividend payments). Profit margins are more than 30% lower than last year (11% net profit margin).Reported Earnings • Nov 07Second quarter 2024 earnings released: EPS: ₹9.14 (vs ₹22.04 in 2Q 2023)Second quarter 2024 results: EPS: ₹9.14 (down from ₹22.04 in 2Q 2023). Revenue: ₹4.79b (down 14% from 2Q 2023). Net income: ₹380.0m (down 59% from 2Q 2023). Profit margin: 7.9% (down from 17% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India.공시 • Oct 12Epigral Limited to Report Q2, 2024 Results on Nov 06, 2023Epigral Limited announced that they will report Q2, 2024 results on Nov 06, 2023Reported Earnings • Aug 06First quarter 2024 earnings released: EPS: ₹7.58 (vs ₹25.94 in 1Q 2023)First quarter 2024 results: EPS: ₹7.58 (down from ₹25.94 in 1Q 2023). Revenue: ₹4.56b (down 14% from 1Q 2023). Net income: ₹315.1m (down 71% from 1Q 2023). Profit margin: 6.9% (down from 20% in 1Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in India.공시 • Jul 29Meghmani Finechem Limited to Report Q1, 2024 Results on Aug 05, 2023Meghmani Finechem Limited announced that they will report Q1, 2024 results at 12:08 PM, Indian Standard Time on Aug 05, 2023공시 • Jun 30Meghmani Finechem Limited Approves Final Equity Dividend for the Financial Year 2022-2023Meghmani Finechem Limited announced that at its Annual General Meeting held on June 27, 2023, approved final equity dividend at 25% that is INR 2.50 per share on 41,550,158 Equity Shares of INR 10 each for the Financial Year 2022-2023.Upcoming Dividend • Jun 13Upcoming dividend of ₹2.50 per share at 0.5% yieldEligible shareholders must have bought the stock before 20 June 2023. Payment date: 27 July 2023. Payout ratio is a comfortable 5.9% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.9%).Recent Insider Transactions • Jun 10Insider recently bought ₹4.8m worth of stockOn the 5th of June, Rameshbhai Patel bought around 5k shares on-market at roughly ₹968 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹4.8m. Insiders have collectively bought ₹44m more in shares than they have sold in the last 12 months.공시 • Jun 04Meghmani Finechem Limited Proposes Final Dividend to the Shareholders for Financial Year 2022- 2023Meghmani Finechem Limited proposed interim dividend paid @25% that is INR 2.50 per share on 4,15,50,158 Equity Shares of INR 10 each fully paid-up, to the shareholders for financial Year 2022- 2023, and to declare final equity Dividend for the financial year 2022-2023.Reported Earnings • Jun 04Full year 2023 earnings released: EPS: ₹85.03 (vs ₹60.84 in FY 2022)Full year 2023 results: EPS: ₹85.03 (up from ₹60.84 in FY 2022). Revenue: ₹22.0b (up 42% from FY 2022). Net income: ₹3.53b (up 40% from FY 2022). Profit margin: 16% (in line with FY 2022). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India.공시 • Jun 03Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023, at 10:30 Indian Standard Time. Agenda: To receive, consider, and adopt the Audited Standalone Financial Statement of the Company for the Financial Year ended March 31, 2023 together with report of the Board of Directors & Auditors thereon; to receive, consider, and adopt the Audited Consolidated Financial Statement of the Company for the Financial Year ended on March 31, 2023 together with report of the Auditors thereon; to confirm interim dividend payment and to declare Final Equity Dividend for the Financial Year 2022-2023; to appoint a Director in place of Mr. Maulik Patel, who retires by rotation, and being eligible, offers himself for re-appointment; to appoint a Director in place of Mr. Kaushal Soparkar, who retires by rotation, and being eligible, offers himself for re-appointment; and to consider other matters.Recent Insider Transactions • Jun 03Insider recently bought ₹4.6m worth of stockOn the 30th of May, Rameshbhai Patel bought around 5k shares on-market at roughly ₹920 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹4.8m. Insiders have collectively bought ₹40m more in shares than they have sold in the last 12 months.Reported Earnings • Apr 26Full year 2023 earnings released: EPS: ₹85.03 (vs ₹60.84 in FY 2022)Full year 2023 results: EPS: ₹85.03 (up from ₹60.84 in FY 2022). Revenue: ₹22.0b (up 42% from FY 2022). Net income: ₹3.53b (up 40% from FY 2022). Profit margin: 16% (in line with FY 2022).Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹962, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 10% over the past year.Recent Insider Transactions • Mar 17Chairman & MD recently bought ₹4.8m worth of stockOn the 14th of March, Maulik Patel bought around 5k shares on-market at roughly ₹968 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹5.1m. Maulik has been a buyer over the last 12 months, purchasing a net total of ₹23m worth in shares.Recent Insider Transactions • Feb 17Chairman & MD recently bought ₹2.9m worth of stockOn the 14th of February, Maulik Patel bought around 3k shares on-market at roughly ₹1,034 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹5.0m. This was Maulik's only on-market trade for the last 12 months.Recent Insider Transactions • Jan 29Insider recently bought ₹5.0m worth of stockOn the 25th of January, Rameshbhai Patel bought around 5k shares on-market at roughly ₹1,044 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹5.8m more in shares than they have sold in the last 12 months.Reported Earnings • Jan 20Third quarter 2023 earnings released: EPS: ₹18.68 (vs ₹23.85 in 3Q 2022)Third quarter 2023 results: EPS: ₹18.68 (down from ₹23.85 in 3Q 2022). Revenue: ₹5.38b (up 7.8% from 3Q 2022). Net income: ₹772.0m (down 22% from 3Q 2022). Profit margin: 14% (down from 20% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India.공시 • Jan 20Meghmani Finechem Limited Declares Maiden Interim Dividend for the Year Financial Year 2022-23, Payable on or After 08 February, 2023The Board of Directors of the Meghmani Finechem Limited meeting held on 19 January, 2023 has also declared maiden Interim Dividend at INR 2.50 (i.e. 25%) per Equity Share on 4,15,50,158 Equity Shares of INR 10 each for the year financial year 2022-23. The Interim Dividend will be paid on or after 08 February, 2023.공시 • Jan 12Meghmani Finechem Limited to Report Q3, 2023 Results on Jan 19, 2023Meghmani Finechem Limited announced that they will report Q3, 2023 results on Jan 19, 2023Reported Earnings • Oct 21Second quarter 2023 earnings released: EPS: ₹22.04 (vs ₹23.85 in 2Q 2022)Second quarter 2023 results: EPS: ₹22.04 (down from ₹23.85 in 2Q 2022). Revenue: ₹5.57b (up 12% from 2Q 2022). Net income: ₹915.7m (down 7.6% from 2Q 2022). Profit margin: 16% (down from 20% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India.Valuation Update With 7 Day Price Move • Sep 26Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹1,433, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 101% over the past year.Reported Earnings • Jul 22First quarter 2023 earnings released: EPS: ₹25.94 (vs ₹7.89 in 1Q 2022)First quarter 2023 results: EPS: ₹25.94 (up from ₹7.89 in 1Q 2022). Revenue: ₹5.33b (up 106% from 1Q 2022). Net income: ₹1.08b (up 229% from 1Q 2022). Profit margin: 20% (up from 13% in 1Q 2022). The increase in margin was driven by higher revenue.공시 • Jul 08Meghmani Finechem Limited to Report Q1, 2023 Results on Jul 21, 2022Meghmani Finechem Limited announced that they will report Q1, 2023 results on Jul 21, 2022Reported Earnings • Jun 05Full year 2022 earnings released: EPS: ₹60.84 (vs ₹24.27 in FY 2021)Full year 2022 results: EPS: ₹60.84 (up from ₹24.27 in FY 2021). Revenue: ₹15.5b (up 87% from FY 2021). Net income: ₹2.53b (up 151% from FY 2021). Profit margin: 16% (up from 12% in FY 2021). The increase in margin was driven by higher revenue.공시 • Jun 04Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2022Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2022, at 10:30 Indian Standard Time. Agenda: To consider the Audited Standalone Financial Statement of the Company for the financial year ended on 31 March, 2022 together with report of the Board of Directors & Auditors thereon; to consider the Audited consolidated Financial Statement of the Company for the financial year ended on 31 March, 2022 together with report of the Board of Directors & Auditors thereon; to consider directorate reappointments; and to consider other matters.Valuation Update With 7 Day Price Move • May 20Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹1,398, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 18x in the Chemicals industry in India.Reported Earnings • Apr 27Full year 2022 earnings released: EPS: ₹60.84 (vs ₹24.27 in FY 2021)Full year 2022 results: EPS: ₹60.84 (up from ₹24.27 in FY 2021). Revenue: ₹15.6b (up 87% from FY 2021). Net income: ₹2.53b (up 151% from FY 2021). Profit margin: 16% (up from 12% in FY 2021). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹1,170, the stock trades at a trailing P/E ratio of 48.2x. Average trailing P/E is 20x in the Chemicals industry in India.공시 • Apr 05Meghmani Finechem Limited to Report Fiscal Year 2022 Results on Apr 25, 2022Meghmani Finechem Limited announced that they will report fiscal year 2022 results on Apr 25, 2022Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹924, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 18x in the Chemicals industry in India.Recent Insider Transactions • Mar 11CEO, MD & Director recently bought ₹799k worth of stockOn the 8th of March, Kaushal Soparkar bought around 1k shares on-market at roughly ₹799 per share. In the last 3 months, there was an even bigger purchase from another insider worth ₹7.6m. Kaushal has been a buyer over the last 12 months, purchasing a net total of ₹7.3m worth in shares.Recent Insider Transactions • Dec 17Insider recently bought ₹762k worth of stockOn the 15th of December, Dhiren Goyal bought around 1k shares on-market at roughly ₹762 per share. In the last 3 months, there was an even bigger purchase from another insider worth ₹13m. Insiders have collectively bought ₹99m more in shares than they have sold in the last 12 months.Valuation Update With 7 Day Price Move • Dec 06Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹789, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 17x in the Chemicals industry in India.Recent Insider Transactions • Nov 25Insider recently bought ₹8.3m worth of stockOn the 22nd of November, Kalpanaben Patel bought around 12k shares on-market at roughly ₹709 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹13m more in shares than they have sold in the last 12 months.Valuation Update With 7 Day Price Move • Oct 01Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹858, the stock trades at a trailing P/E ratio of 35.3x. Average trailing P/E is 19x in the Chemicals industry in India.Board Change • Sep 14No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Additional Director Karana Patel was the last director to join the board, commencing their role in 2016. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Sep 13No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Additional Director Karana Patel was the last director to join the board, commencing their role in 2016. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Sep 11No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Additional Director Karana Patel was the last director to join the board, commencing their role in 2016. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Sep 09No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Additional Director Karana Patel was the last director to join the board, commencing their role in 2016. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Sep 07MD & Additional Director recently bought ₹5.0m worth of stockOn the 3rd of September, Kaushal Soparkar bought around 8k shares on-market at roughly ₹662 per share. This was the largest purchase by an insider in the last 3 months. This was Kaushal's only on-market trade for the last 12 months.Board Change • Sep 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Additional Director Karana Patel was the last director to join the board, commencing their role in 2016. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.이익 및 매출 성장 예측BSE:543332 - 애널리스트 향후 추정치 및 과거 재무 데이터 (INR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수3/31/202838,4294,6061,4976,49713/31/202733,9204,046-8875,11313/31/202625,2723,3204144,355N/A12/31/202524,1873,379N/AN/AN/A9/30/202524,6684,0241,4254,894N/A6/30/202525,0554,325N/AN/AN/A3/31/202525,5013,5772,4594,406N/A12/31/202424,4713,481N/AN/AN/A9/30/202422,7342,9351,7514,323N/A6/30/202421,2552,502N/AN/AN/A3/31/202419,2921,959-83,976N/A12/31/202319,6671,953N/AN/AN/A9/30/202320,3312,2346795,174N/A6/30/202321,1042,770N/AN/AN/A3/31/202321,8843,5332,0976,262N/A12/31/202221,2503,756N/AN/AN/A9/30/202220,0933,6821554,202N/A6/30/202217,9343,236N/AN/AN/A3/31/202215,5092,528-1,7252,838N/A3/31/20218,2861,0083242,292N/A3/31/20206,0981,141-2,0461,646N/A3/31/20197,1041,828N/A2,613N/A3/31/20185,9751,555N/A2,249N/A3/31/20173,921665N/A1,385N/A3/31/20163,982672N/A1,234N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 543332 의 연간 예상 수익 증가율(16.1%)이 saving rate(6.9%)보다 높습니다.수익 vs 시장: 543332 의 연간 수익(16.1%)이 Indian 시장(16.2%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: 543332 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 543332 의 수익(연간 20.2%)이 Indian 시장(연간 10.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 543332 의 수익(연간 20.2%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 543332의 자본 수익률은 3년 후 16.4%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 14:06종가2026/05/22 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Epigral Limited는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullBP Wealth Management Private Limitednull nullEmkay Global Financial Services Ltd.Meet VoraEmkay Global Financial Services Ltd.
Price Target Changed • Jan 07Price target decreased by 23% to ₹2,000Down from ₹2,600, the current price target is provided by 1 analyst. New target price is 73% above last closing price of ₹1,156. Stock is down 37% over the past year. The company posted earnings per share of ₹84.68 last year.
New Risk • May 18New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
공시 • May 14Epigral Limited, Annual General Meeting, Jun 08, 2026Epigral Limited, Annual General Meeting, Jun 08, 2026, at 11:00 Indian Standard Time.
Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹76.95 (vs ₹84.68 in FY 2025)Full year 2026 results: EPS: ₹76.95 (down from ₹84.68 in FY 2025). Revenue: ₹25.4b (flat on FY 2025). Net income: ₹3.32b (down 7.2% from FY 2025). Profit margin: 13% (in line with FY 2025). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 12% per year.
공시 • Apr 29Epigral Limited to Report Q4, 2026 Results on May 02, 2026Epigral Limited announced that they will report Q4, 2026 results at 9:08 AM, Indian Standard Time on May 02, 2026
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹951, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 25x in the Chemicals industry in India. Negligible returns to shareholders over past three years.
Reported Earnings • Jan 31Third quarter 2026 earnings released: EPS: ₹9.07 (vs ₹24.25 in 3Q 2025)Third quarter 2026 results: EPS: ₹9.07 (down from ₹24.25 in 3Q 2025). Revenue: ₹5.97b (down 7.5% from 3Q 2025). Net income: ₹391.1m (down 62% from 3Q 2025). Profit margin: 6.5% (down from 16% in 3Q 2025). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
공시 • Jan 20Epigral Limited to Report Q3, 2026 Results on Jan 30, 2026Epigral Limited announced that they will report Q3, 2026 results on Jan 30, 2026
Price Target Changed • Jan 07Price target decreased by 23% to ₹2,000Down from ₹2,600, the current price target is provided by 1 analyst. New target price is 73% above last closing price of ₹1,156. Stock is down 37% over the past year. The company posted earnings per share of ₹84.68 last year.
Reported Earnings • Nov 11Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2026 results: EPS: ₹11.87 (down from ₹19.57 in 2Q 2025). Revenue: ₹5.89b (down 5.9% from 2Q 2025). Net income: ₹512.2m (down 37% from 2Q 2025). Profit margin: 8.7% (down from 13% in 2Q 2025). The decrease in margin was driven by lower revenue. Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) missed analyst estimates by 16%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 7% per year.
공시 • Nov 04Epigral Limited to Report Q2, 2026 Results on Nov 10, 2025Epigral Limited announced that they will report Q2, 2026 results on Nov 10, 2025
Reported Earnings • Aug 03First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2026 results: EPS: ₹37.25 (up from ₹20.67 in 1Q 2025). Revenue: ₹6.07b (down 6.9% from 1Q 2025). Net income: ₹1.61b (up 87% from 1Q 2025). Profit margin: 27% (up from 13% in 1Q 2025). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 98%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹2,085, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 43% over the past three years.
공시 • Jul 28Epigral Limited to Report Q1, 2026 Results on Aug 02, 2025Epigral Limited announced that they will report Q1, 2026 results at 9:08 AM, Indian Standard Time on Aug 02, 2025
공시 • Jun 30Epigral Limited Approves Final Dividend for the Financial Year Ended 31 March, 2025Epigral Limited announced that at its AGM held on June 28, 2025, approved payment of Interim Dividend of INR 2.50 (25%) per equity share of INR 10 each and to declare Final Dividend of INR 3.50 (35%) per equity share of INR 10 each fully paid-up for the Financial Year ended 31st March, 2025.
Upcoming Dividend • Jun 16Upcoming dividend of ₹3.50 per shareEligible shareholders must have bought the stock before 20 June 2025. Payment date: 28 July 2025. Payout ratio is a comfortable 7.1% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).
Reported Earnings • Jun 09Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: EPS: ₹84.68 (up from ₹47.14 in FY 2024). Revenue: ₹25.5b (up 32% from FY 2024). Net income: ₹3.58b (up 83% from FY 2024). Profit margin: 14% (up from 10% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) exceeded analyst estimates by 3.8%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
Declared Dividend • Jun 02Final dividend of ₹3.50 announcedShareholders will receive a dividend of ₹3.50. Ex-date: 20th June 2025 Payment date: 28th July 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (12% cash payout ratio). The dividend has increased by an average of 18% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 71% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공시 • May 30Epigral Limited, Annual General Meeting, Jun 28, 2025Epigral Limited, Annual General Meeting, Jun 28, 2025, at 10:30 Indian Standard Time.
Reported Earnings • May 07Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: EPS: ₹84.68 (up from ₹47.14 in FY 2024). Revenue: ₹25.7b (up 33% from FY 2024). Net income: ₹3.58b (up 83% from FY 2024). Profit margin: 14% (up from 10% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) exceeded analyst estimates by 3.8%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
공시 • Apr 23Epigral Limited to Report Q4, 2025 Results on May 05, 2025Epigral Limited announced that they will report Q4, 2025 results on May 05, 2025
New Risk • Mar 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (64% net debt to equity). Share price has been volatile over the past 3 months (8.1% average weekly change).
Valuation Update With 7 Day Price Move • Mar 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹1,866, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 26x in the Chemicals industry in India. Total returns to shareholders of 112% over the past three years.
공시 • Feb 28Epigral Limited Announces Cessation of Bhavin Parikh as an Independent Woman DirectorThe Board of Directors of Epigral Limited vide Circular Resolution, passed on 28th February, 2025, have inter-alia considered and approved cessation of Ms. Nirali Bhavin Parikh as an Independent Woman Director of the Company with effect from close of business hours on 28th February, 2025 pursuant to completion of her second term of five consecutive years.
Upcoming Dividend • Jan 31Upcoming dividend of ₹2.50 per shareEligible shareholders must have bought the stock before 07 February 2025. Payment date: 26 February 2025. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).
Reported Earnings • Jan 28Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: EPS: ₹24.25 (up from ₹11.81 in 3Q 2024). Revenue: ₹6.49b (up 38% from 3Q 2024). Net income: ₹1.04b (up 111% from 3Q 2024). Profit margin: 16% (up from 10% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) also surpassed analyst estimates by 25%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.
공시 • Jan 27Epigral Limited Declares Interim Dividend for the Financial Year 2024-25Epigral Limited announced at the SBM held on January 27, 2025, the board approved declared interim dividend of INR 2.50 (25%) per Equity Share of face value of INR 10 each for the Financial Year 2024-25 and has fixed 7th February, 2025 as `Record Date' pursuant to regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for ascertaining eligibility of Members for the payment of aforesaid Interim Dividend.
공시 • Jan 18Epigral Limited to Report Q3, 2025 Results on Jan 27, 2025Epigral Limited announced that they will report Q3, 2025 results on Jan 27, 2025
Reported Earnings • Nov 10Second quarter 2025 earnings released: EPS: ₹19.57 (vs ₹9.14 in 2Q 2024)Second quarter 2025 results: EPS: ₹19.57 (up from ₹9.14 in 2Q 2024). Revenue: ₹6.32b (up 32% from 2Q 2024). Net income: ₹813.0m (up 114% from 2Q 2024). Profit margin: 13% (up from 7.9% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India.
공시 • Oct 31Epigral Limited to Report Q2, 2025 Results on Nov 09, 2024Epigral Limited announced that they will report Q2, 2025 results at 12:08 PM, Indian Standard Time on Nov 09, 2024
Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹2,296, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 197% over the past three years.
New Risk • Sep 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (77% net debt to equity). Share price has been volatile over the past 3 months (8.7% average weekly change).
Reported Earnings • Jul 25First quarter 2025 earnings released: EPS: ₹20.67 (vs ₹7.58 in 1Q 2024)First quarter 2025 results: EPS: ₹20.67 (up from ₹7.58 in 1Q 2024). Revenue: ₹6.51b (up 43% from 1Q 2024). Net income: ₹858.7m (up 173% from 1Q 2024). Profit margin: 13% (up from 6.9% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in India.
공시 • Jul 16Epigral Limited to Report Q1, 2025 Results on Jul 24, 2024Epigral Limited announced that they will report Q1, 2025 results on Jul 24, 2024
공시 • Jul 10Epigral Limited Approves Final Dividend for the Financial Year 2024Epigral Limited announced that at its Annual General Meeting held on July 9, 2024, approved final dividend of INR 5.00 (50%) per equity share of INR 10 each for the Financial Year 2023-2024.
Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹1,559, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 49% over the past year.
Upcoming Dividend • Jun 27Upcoming dividend of ₹5.00 per shareEligible shareholders must have bought the stock before 02 July 2024. Payment date: 08 August 2024. Payout ratio is a comfortable 11% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.7%).
Reported Earnings • Jun 20Full year 2024 earnings released: EPS: ₹47.14 (vs ₹85.03 in FY 2023)Full year 2024 results: EPS: ₹47.14 (down from ₹85.03 in FY 2023). Revenue: ₹19.3b (down 12% from FY 2023). Net income: ₹1.96b (down 45% from FY 2023). Profit margin: 10% (down from 16% in FY 2023). The decrease in margin was driven by lower revenue.
Declared Dividend • Jun 13Dividend of ₹5.00 announcedShareholders will receive a dividend of ₹5.00. Ex-date: 2nd July 2024 Payment date: 8th August 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (11% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 13% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공시 • Jun 13Epigral Limited, Annual General Meeting, Jul 09, 2024Epigral Limited, Annual General Meeting, Jul 09, 2024, at 10:30 Indian Standard Time.
Board Change • Jun 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 6 highly experienced directors. Independent Non-Executive Director Kanubhai Patel was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 23Full year 2024 earnings released: EPS: ₹47.13 (vs ₹85.03 in FY 2023)Full year 2024 results: EPS: ₹47.13 (down from ₹85.03 in FY 2023). Revenue: ₹19.4b (down 12% from FY 2023). Net income: ₹1.96b (down 45% from FY 2023). Profit margin: 10% (down from 16% in FY 2023). The decrease in margin was driven by lower revenue.
공시 • Apr 23+ 1 more updateEpigral Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024Epigral Limited Recommended final dividend of INR 5.00(50.00%) per equity share on 4,15,50,158 Equity Shares of INR 10/- each for the financial year ended 31st March, 2024, subject to approval of the Shareholders of the Company at the forthcoming Annual General Meeting. The Book Closure and Record Date for this purpose will be intimated in due course.
공시 • Apr 10Epigral Limited to Report Q4, 2024 Results on Apr 22, 2024Epigral Limited announced that they will report Q4, 2024 results on Apr 22, 2024
Valuation Update With 7 Day Price Move • Apr 02Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹1,323, the stock trades at a trailing P/E ratio of 28.2x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 38% over the past year.
Valuation Update With 7 Day Price Move • Feb 21Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹1,219, the stock trades at a trailing P/E ratio of 26x. Average forward P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 21% over the past year.
Reported Earnings • Jan 26Third quarter 2024 earnings released: EPS: ₹11.81 (vs ₹18.58 in 3Q 2023)Third quarter 2024 results: EPS: ₹11.81 (down from ₹18.58 in 3Q 2023). Revenue: ₹4.72b (down 12% from 3Q 2023). Net income: ₹490.8m (down 36% from 3Q 2023). Profit margin: 10% (down from 14% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India.
Buy Or Sell Opportunity • Jan 25Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 9.0% to ₹998. The fair value is estimated to be ₹812, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last year. Earnings per share has declined by 39%.
공시 • Jan 02Epigral Limited to Report Q3, 2024 Results on Jan 24, 2024Epigral Limited announced that they will report Q3, 2024 results on Jan 24, 2024
New Risk • Nov 07New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 11% Last year net profit margin: 18% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks High level of debt (85% net debt to equity). Short dividend paying track record (1 year of continuous dividend payments). Profit margins are more than 30% lower than last year (11% net profit margin).
Reported Earnings • Nov 07Second quarter 2024 earnings released: EPS: ₹9.14 (vs ₹22.04 in 2Q 2023)Second quarter 2024 results: EPS: ₹9.14 (down from ₹22.04 in 2Q 2023). Revenue: ₹4.79b (down 14% from 2Q 2023). Net income: ₹380.0m (down 59% from 2Q 2023). Profit margin: 7.9% (down from 17% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India.
공시 • Oct 12Epigral Limited to Report Q2, 2024 Results on Nov 06, 2023Epigral Limited announced that they will report Q2, 2024 results on Nov 06, 2023
Reported Earnings • Aug 06First quarter 2024 earnings released: EPS: ₹7.58 (vs ₹25.94 in 1Q 2023)First quarter 2024 results: EPS: ₹7.58 (down from ₹25.94 in 1Q 2023). Revenue: ₹4.56b (down 14% from 1Q 2023). Net income: ₹315.1m (down 71% from 1Q 2023). Profit margin: 6.9% (down from 20% in 1Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in India.
공시 • Jul 29Meghmani Finechem Limited to Report Q1, 2024 Results on Aug 05, 2023Meghmani Finechem Limited announced that they will report Q1, 2024 results at 12:08 PM, Indian Standard Time on Aug 05, 2023
공시 • Jun 30Meghmani Finechem Limited Approves Final Equity Dividend for the Financial Year 2022-2023Meghmani Finechem Limited announced that at its Annual General Meeting held on June 27, 2023, approved final equity dividend at 25% that is INR 2.50 per share on 41,550,158 Equity Shares of INR 10 each for the Financial Year 2022-2023.
Upcoming Dividend • Jun 13Upcoming dividend of ₹2.50 per share at 0.5% yieldEligible shareholders must have bought the stock before 20 June 2023. Payment date: 27 July 2023. Payout ratio is a comfortable 5.9% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.9%).
Recent Insider Transactions • Jun 10Insider recently bought ₹4.8m worth of stockOn the 5th of June, Rameshbhai Patel bought around 5k shares on-market at roughly ₹968 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹4.8m. Insiders have collectively bought ₹44m more in shares than they have sold in the last 12 months.
공시 • Jun 04Meghmani Finechem Limited Proposes Final Dividend to the Shareholders for Financial Year 2022- 2023Meghmani Finechem Limited proposed interim dividend paid @25% that is INR 2.50 per share on 4,15,50,158 Equity Shares of INR 10 each fully paid-up, to the shareholders for financial Year 2022- 2023, and to declare final equity Dividend for the financial year 2022-2023.
Reported Earnings • Jun 04Full year 2023 earnings released: EPS: ₹85.03 (vs ₹60.84 in FY 2022)Full year 2023 results: EPS: ₹85.03 (up from ₹60.84 in FY 2022). Revenue: ₹22.0b (up 42% from FY 2022). Net income: ₹3.53b (up 40% from FY 2022). Profit margin: 16% (in line with FY 2022). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India.
공시 • Jun 03Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023, at 10:30 Indian Standard Time. Agenda: To receive, consider, and adopt the Audited Standalone Financial Statement of the Company for the Financial Year ended March 31, 2023 together with report of the Board of Directors & Auditors thereon; to receive, consider, and adopt the Audited Consolidated Financial Statement of the Company for the Financial Year ended on March 31, 2023 together with report of the Auditors thereon; to confirm interim dividend payment and to declare Final Equity Dividend for the Financial Year 2022-2023; to appoint a Director in place of Mr. Maulik Patel, who retires by rotation, and being eligible, offers himself for re-appointment; to appoint a Director in place of Mr. Kaushal Soparkar, who retires by rotation, and being eligible, offers himself for re-appointment; and to consider other matters.
Recent Insider Transactions • Jun 03Insider recently bought ₹4.6m worth of stockOn the 30th of May, Rameshbhai Patel bought around 5k shares on-market at roughly ₹920 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹4.8m. Insiders have collectively bought ₹40m more in shares than they have sold in the last 12 months.
Reported Earnings • Apr 26Full year 2023 earnings released: EPS: ₹85.03 (vs ₹60.84 in FY 2022)Full year 2023 results: EPS: ₹85.03 (up from ₹60.84 in FY 2022). Revenue: ₹22.0b (up 42% from FY 2022). Net income: ₹3.53b (up 40% from FY 2022). Profit margin: 16% (in line with FY 2022).
Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹962, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 10% over the past year.
Recent Insider Transactions • Mar 17Chairman & MD recently bought ₹4.8m worth of stockOn the 14th of March, Maulik Patel bought around 5k shares on-market at roughly ₹968 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹5.1m. Maulik has been a buyer over the last 12 months, purchasing a net total of ₹23m worth in shares.
Recent Insider Transactions • Feb 17Chairman & MD recently bought ₹2.9m worth of stockOn the 14th of February, Maulik Patel bought around 3k shares on-market at roughly ₹1,034 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹5.0m. This was Maulik's only on-market trade for the last 12 months.
Recent Insider Transactions • Jan 29Insider recently bought ₹5.0m worth of stockOn the 25th of January, Rameshbhai Patel bought around 5k shares on-market at roughly ₹1,044 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹5.8m more in shares than they have sold in the last 12 months.
Reported Earnings • Jan 20Third quarter 2023 earnings released: EPS: ₹18.68 (vs ₹23.85 in 3Q 2022)Third quarter 2023 results: EPS: ₹18.68 (down from ₹23.85 in 3Q 2022). Revenue: ₹5.38b (up 7.8% from 3Q 2022). Net income: ₹772.0m (down 22% from 3Q 2022). Profit margin: 14% (down from 20% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India.
공시 • Jan 20Meghmani Finechem Limited Declares Maiden Interim Dividend for the Year Financial Year 2022-23, Payable on or After 08 February, 2023The Board of Directors of the Meghmani Finechem Limited meeting held on 19 January, 2023 has also declared maiden Interim Dividend at INR 2.50 (i.e. 25%) per Equity Share on 4,15,50,158 Equity Shares of INR 10 each for the year financial year 2022-23. The Interim Dividend will be paid on or after 08 February, 2023.
공시 • Jan 12Meghmani Finechem Limited to Report Q3, 2023 Results on Jan 19, 2023Meghmani Finechem Limited announced that they will report Q3, 2023 results on Jan 19, 2023
Reported Earnings • Oct 21Second quarter 2023 earnings released: EPS: ₹22.04 (vs ₹23.85 in 2Q 2022)Second quarter 2023 results: EPS: ₹22.04 (down from ₹23.85 in 2Q 2022). Revenue: ₹5.57b (up 12% from 2Q 2022). Net income: ₹915.7m (down 7.6% from 2Q 2022). Profit margin: 16% (down from 20% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India.
Valuation Update With 7 Day Price Move • Sep 26Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹1,433, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 101% over the past year.
Reported Earnings • Jul 22First quarter 2023 earnings released: EPS: ₹25.94 (vs ₹7.89 in 1Q 2022)First quarter 2023 results: EPS: ₹25.94 (up from ₹7.89 in 1Q 2022). Revenue: ₹5.33b (up 106% from 1Q 2022). Net income: ₹1.08b (up 229% from 1Q 2022). Profit margin: 20% (up from 13% in 1Q 2022). The increase in margin was driven by higher revenue.
공시 • Jul 08Meghmani Finechem Limited to Report Q1, 2023 Results on Jul 21, 2022Meghmani Finechem Limited announced that they will report Q1, 2023 results on Jul 21, 2022
Reported Earnings • Jun 05Full year 2022 earnings released: EPS: ₹60.84 (vs ₹24.27 in FY 2021)Full year 2022 results: EPS: ₹60.84 (up from ₹24.27 in FY 2021). Revenue: ₹15.5b (up 87% from FY 2021). Net income: ₹2.53b (up 151% from FY 2021). Profit margin: 16% (up from 12% in FY 2021). The increase in margin was driven by higher revenue.
공시 • Jun 04Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2022Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2022, at 10:30 Indian Standard Time. Agenda: To consider the Audited Standalone Financial Statement of the Company for the financial year ended on 31 March, 2022 together with report of the Board of Directors & Auditors thereon; to consider the Audited consolidated Financial Statement of the Company for the financial year ended on 31 March, 2022 together with report of the Board of Directors & Auditors thereon; to consider directorate reappointments; and to consider other matters.
Valuation Update With 7 Day Price Move • May 20Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹1,398, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 18x in the Chemicals industry in India.
Reported Earnings • Apr 27Full year 2022 earnings released: EPS: ₹60.84 (vs ₹24.27 in FY 2021)Full year 2022 results: EPS: ₹60.84 (up from ₹24.27 in FY 2021). Revenue: ₹15.6b (up 87% from FY 2021). Net income: ₹2.53b (up 151% from FY 2021). Profit margin: 16% (up from 12% in FY 2021). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹1,170, the stock trades at a trailing P/E ratio of 48.2x. Average trailing P/E is 20x in the Chemicals industry in India.
공시 • Apr 05Meghmani Finechem Limited to Report Fiscal Year 2022 Results on Apr 25, 2022Meghmani Finechem Limited announced that they will report fiscal year 2022 results on Apr 25, 2022
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹924, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 18x in the Chemicals industry in India.
Recent Insider Transactions • Mar 11CEO, MD & Director recently bought ₹799k worth of stockOn the 8th of March, Kaushal Soparkar bought around 1k shares on-market at roughly ₹799 per share. In the last 3 months, there was an even bigger purchase from another insider worth ₹7.6m. Kaushal has been a buyer over the last 12 months, purchasing a net total of ₹7.3m worth in shares.
Recent Insider Transactions • Dec 17Insider recently bought ₹762k worth of stockOn the 15th of December, Dhiren Goyal bought around 1k shares on-market at roughly ₹762 per share. In the last 3 months, there was an even bigger purchase from another insider worth ₹13m. Insiders have collectively bought ₹99m more in shares than they have sold in the last 12 months.
Valuation Update With 7 Day Price Move • Dec 06Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹789, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 17x in the Chemicals industry in India.
Recent Insider Transactions • Nov 25Insider recently bought ₹8.3m worth of stockOn the 22nd of November, Kalpanaben Patel bought around 12k shares on-market at roughly ₹709 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹13m more in shares than they have sold in the last 12 months.
Valuation Update With 7 Day Price Move • Oct 01Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹858, the stock trades at a trailing P/E ratio of 35.3x. Average trailing P/E is 19x in the Chemicals industry in India.
Board Change • Sep 14No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Additional Director Karana Patel was the last director to join the board, commencing their role in 2016. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Sep 13No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Additional Director Karana Patel was the last director to join the board, commencing their role in 2016. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Sep 11No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Additional Director Karana Patel was the last director to join the board, commencing their role in 2016. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Sep 09No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Additional Director Karana Patel was the last director to join the board, commencing their role in 2016. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Sep 07MD & Additional Director recently bought ₹5.0m worth of stockOn the 3rd of September, Kaushal Soparkar bought around 8k shares on-market at roughly ₹662 per share. This was the largest purchase by an insider in the last 3 months. This was Kaushal's only on-market trade for the last 12 months.
Board Change • Sep 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Additional Director Karana Patel was the last director to join the board, commencing their role in 2016. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.